vs
Side-by-side financial comparison of Gossamer Bio, Inc. (GOSS) and SWK Holdings Corp (SWKH). Click either name above to swap in a different company.
Gossamer Bio, Inc. is the larger business by last-quarter revenue ($13.8M vs $8.7M, roughly 1.6× SWK Holdings Corp). On growth, Gossamer Bio, Inc. posted the faster year-over-year revenue change (47.1% vs -29.7%).
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
SWK Holdings Corp is a specialty finance firm focused on the healthcare and life sciences sectors. It provides tailored financing solutions including royalty monetization, structured debt, and asset-backed lending to biotech, pharmaceutical, medical device and diagnostic companies, with its core market centered in North America.
GOSS vs SWKH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $8.7M |
| Net Profit | $-47.2M | $-19.4M |
| Gross Margin | — | — |
| Operating Margin | -333.6% | 9.9% |
| Net Margin | -342.3% | — |
| Revenue YoY | 47.1% | -29.7% |
| Net Profit YoY | -43.0% | -430.2% |
| EPS (diluted) | $-0.21 | $-1.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $8.7M | ||
| Q3 25 | $13.3M | $10.9M | ||
| Q2 25 | — | $10.1M | ||
| Q1 25 | — | $11.8M | ||
| Q4 24 | — | $12.4M | ||
| Q3 24 | — | $10.4M | ||
| Q2 24 | $95.8M | $10.8M | ||
| Q1 24 | $0 | $11.4M |
| Q4 25 | $-47.2M | $-19.4M | ||
| Q3 25 | $-48.2M | $8.8M | ||
| Q2 25 | — | $3.5M | ||
| Q1 25 | — | $4.5M | ||
| Q4 24 | — | $5.9M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | $49.2M | $3.7M | ||
| Q1 24 | $-41.9M | $468.0K |
| Q4 25 | -333.6% | 9.9% | ||
| Q3 25 | -369.4% | 61.3% | ||
| Q2 25 | — | 46.1% | ||
| Q1 25 | — | 68.6% | ||
| Q4 24 | — | 44.7% | ||
| Q3 24 | — | 39.2% | ||
| Q2 24 | 54.3% | 8.3% | ||
| Q1 24 | — | 9.5% |
| Q4 25 | -342.3% | — | ||
| Q3 25 | -362.7% | 80.7% | ||
| Q2 25 | — | 35.2% | ||
| Q1 25 | — | 38.4% | ||
| Q4 24 | — | 47.5% | ||
| Q3 24 | — | 33.3% | ||
| Q2 24 | 51.4% | 33.9% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | $-0.21 | $-1.59 | ||
| Q3 25 | $-0.21 | $0.72 | ||
| Q2 25 | — | $0.29 | ||
| Q1 25 | — | $0.37 | ||
| Q4 24 | — | $0.47 | ||
| Q3 24 | — | $0.28 | ||
| Q2 24 | $0.22 | $0.30 | ||
| Q1 24 | $-0.19 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $136.9M | $42.8M |
| Total DebtLower is stronger | — | $33.0M |
| Stockholders' EquityBook value | $-122.8M | $235.1M |
| Total Assets | $172.2M | $272.4M |
| Debt / EquityLower = less leverage | — | 0.14× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $136.9M | $42.8M | ||
| Q3 25 | $180.2M | $10.2M | ||
| Q2 25 | — | $8.0M | ||
| Q1 25 | — | $29.8M | ||
| Q4 24 | — | $5.9M | ||
| Q3 24 | — | $17.2M | ||
| Q2 24 | $354.5M | $5.5M | ||
| Q1 24 | $244.4M | $5.5M |
| Q4 25 | — | $33.0M | ||
| Q3 25 | — | $33.0M | ||
| Q2 25 | — | $33.0M | ||
| Q1 25 | — | $33.0M | ||
| Q4 24 | — | $33.0M | ||
| Q3 24 | — | $33.0M | ||
| Q2 24 | — | $33.0M | ||
| Q1 24 | — | $33.0M |
| Q4 25 | $-122.8M | $235.1M | ||
| Q3 25 | $-82.3M | $254.2M | ||
| Q2 25 | — | $246.5M | ||
| Q1 25 | — | $292.7M | ||
| Q4 24 | — | $288.7M | ||
| Q3 24 | — | $283.4M | ||
| Q2 24 | $81.5M | $282.8M | ||
| Q1 24 | $26.7M | $279.9M |
| Q4 25 | $172.2M | $272.4M | ||
| Q3 25 | $208.8M | $289.4M | ||
| Q2 25 | — | $285.7M | ||
| Q1 25 | — | $331.3M | ||
| Q4 24 | — | $332.2M | ||
| Q3 24 | — | $321.3M | ||
| Q2 24 | $373.4M | $321.0M | ||
| Q1 24 | $259.4M | $322.0M |
| Q4 25 | — | 0.14× | ||
| Q3 25 | — | 0.13× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 0.12× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.3M | $27.3M |
| Free Cash FlowOCF − Capex | — | $26.8M |
| FCF MarginFCF / Revenue | — | 308.1% |
| Capex IntensityCapex / Revenue | 0.0% | 5.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $43.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.3M | $27.3M | ||
| Q3 25 | $-36.2M | $906.0K | ||
| Q2 25 | — | $7.8M | ||
| Q1 25 | — | $8.3M | ||
| Q4 24 | — | $23.0M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | $116.3M | $5.4M | ||
| Q1 24 | $-52.3M | $4.4M |
| Q4 25 | — | $26.8M | ||
| Q3 25 | — | $557.0K | ||
| Q2 25 | — | $7.7M | ||
| Q1 25 | — | $8.2M | ||
| Q4 24 | — | $22.9M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $5.4M | ||
| Q1 24 | — | — |
| Q4 25 | — | 308.1% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | 77.0% | ||
| Q1 25 | — | 69.1% | ||
| Q4 24 | — | 185.3% | ||
| Q3 24 | — | 60.4% | ||
| Q2 24 | — | 49.7% | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | 5.9% | ||
| Q3 25 | 0.0% | 3.2% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | 0.0% | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | 2.21× | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 3.93× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | 2.36× | 1.47× | ||
| Q1 24 | — | 9.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GOSS
Segment breakdown not available.
SWKH
| Finance Receivables Segment | $8.4M | 96% |
| Other | $329.0K | 4% |
